MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
- None.
- None.
Insights
The strategic partnership between MaxCyte and Be Biopharma represents a significant collaboration in the biotechnology sector, particularly within the cell therapy landscape. MaxCyte's Flow Electroporation® technology and ExPERT™ platform are critical tools in the development of advanced cell-based therapies. By utilizing these platforms, Be Biopharma aims to enhance their Engineered B Cell Medicines (BCMs) programs, which could offer novel treatments for patients with genetic diseases and cancer.
From a biotechnology perspective, the non-exclusive nature of the agreement allows MaxCyte to maintain its business model of broad licensing, which is a common approach in the industry to maximize technology utilization and revenue streams. The deal structure, including annual licensing fees and sales-based payments, is designed to benefit MaxCyte in both the short and long term, providing a steady income and potential growth tied to the success of Be Biopharma's BCMs. This kind of revenue model is generally well-received by investors as it implies a continuous revenue source rather than one-time payments.
MaxCyte's announcement of its 27th clinical/commercial partnership is a testament to the company's growth strategy and its ability to attract partners in the competitive cell engineering space. The financial implications of this partnership for MaxCyte include diversified revenue through annual licensing fees and program-related payments, which are likely to be reflected positively in the company's financial statements. This diversification is particularly important as it reduces reliance on any single income source and provides a buffer against market volatility.
For investors, the key interest lies in the potential for sales-based payments, which are contingent on the commercial success of Be Biopharma's BCMs. These payments could significantly impact MaxCyte's revenue and profitability if Be Biopharma's therapies achieve market success. However, the inherent risks of clinical development in biotechnology, including the possibility of clinical trial failures or regulatory hurdles, should be considered when evaluating the long-term financial impact of this partnership.
The utilization of MaxCyte's technology in Be Biopharma's BCMs programs is poised to push the envelope in the treatment of genetic diseases and cancer. Engineered B Cell Medicines represent a burgeoning field in cell therapy, aiming to leverage the body's own immune system to fight diseases more effectively. MaxCyte's electroporation technology facilitates the introduction of genetic material into B cells, which can then be engineered to produce therapeutic proteins or antibodies.
What stands out in this partnership is the potential for BCMs to address unmet medical needs. The success of these therapies could lead to a paradigm shift in treatment strategies, potentially offering patients more targeted and effective options. The clinical success of these programs will be pivotal not only for patient outcomes but also for the financial success of both MaxCyte and Be Biopharma. The market for cell-based therapies is rapidly growing and successful BCMs could capture a significant share, thus having a notable impact on the companies' valuations and investor interest.
Be Biopharma to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform within its Engineered B Cell Medicines programs
ROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications and Be Biopharma (“Be Bio”), a company pioneering the development of Engineered B Cell Medicines (BCMs) to dramatically improve the lives of patients who are living with genetic diseases, cancer, and other serious conditions, today announced the signing of a strategic platform license (SPL) to support the development of Be Bio’s BCMs programs.
Under the terms of the agreement, Be Bio obtains non-exclusive research, clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform. In return, MaxCyte is entitled to receive annual licensing fees and program-related revenue.
“We are thrilled to support Be Bio’s pioneering efforts in the creation of Engineered B Cell Medicines (BCMs),” said Maher Masoud, President and CEO of MaxCyte. “Our technology and expertise will empower them to unlock the potential of human B cells to address the unmet medical needs of patients with genetic diseases, cancer, and beyond. This new class of therapies could be transformative, and we are excited to be part of this journey.”
MaxCyte’s ExPERT™ instrument portfolio is the next generation of leading, clinically-validated electroporation technology for complex and scalable cell engineering. By delivering high transfection efficiency, seamless scalability and enhanced functionality, the ExPERT™ platform delivers the high-end performance essential to enabling the next wave of biological and cellular therapeutics. Be Bio is MaxCyte’s 27th clinical/commercial partnership overall, each of which generates pre-commercial milestone revenue, the vast majority of which include sales-based payments.
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients’ lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today’s processes to innovate tomorrow’s solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on X (formerly Twitter) and LinkedIn.
About Be Biopharma
Be Biopharma (“Be Bio”) is pioneering Engineered B Cell Medicines (BCMs) to dramatically improve the lives of patients who are living with Hemophilia B and other genetic diseases, cancer, and other serious conditions. With eyes locked on the patient, our team of purpose-driven scientists, technologists, manufacturing experts and business builders collaborate to create a bold new class of cell therapies. Be Bio was founded in October 2020 by B cell engineering pioneers David Rawlings, M.D., and Richard James, Ph.D., from Seattle Children’s Research Institute. Be Bio is backed by ARCH Venture Partners, Atlas Venture, RA Capital Management, Alta Partners, Longwood Fund, Bristol Myers Squibb, Takeda Ventures, Seattle Children’s Research Institute and others. Since our founding, Be Bio’s investors have committed over
MaxCyte Contacts:
US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com
US Media Relations
Spectrum Seismic Collaborative
Anya Bolshem
abolshem@spectrumscience.com
+1 732-284-1751
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
UK IR Adviser
ICR Consilium
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@consilium-comms.com
Be Bio Contacts:
Investor Relations
ir@be.bio
Media:
media@be.bio
FAQ
What technology will Be Biopharma use in its Engineered B Cell Medicines programs?
What benefits does MaxCyte offer Be Biopharma through the agreement?
How many clinical/commercial partnerships has MaxCyte formed, including Be Biopharma?
Who is the President and CEO of MaxCyte?
What is the ticker symbol for MaxCyte, Inc.?
